Pernicious Anemia Diagnosis And Treatment Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Pernicious Anemia Diagnosis And Treatment Market Be Worth By 2029?
The market size for diagnosing and treating pernicious anemia has seen considerable progression in the past few years. The market is projected to expand from $1.42 billion in 2024 to $1.51 billion in 2025, marking a compound annual growth rate (CAGR) of 6.7%. Factors contributing to growth during the historical period include increased awareness of vitamin B12 deficiency, a rise in cases of autoimmune disorders, growth in the elderly population, enhanced education amongst physicians on anemia topics, and the provision of vitamin B12 in oral and injectable forms.
The market size for the diagnosis and treatment of pernicious anemia is predicted to witness robust expansion in the upcoming years, projected to reach $1.96 billion by 2029, with a CAGR of 6.7%. Developing telemedicine services, increasing demand for preemptive diagnosis, a heightened emphasis on personalized medicine, governmental diagnostic programs, and an escalating inclination towards non-invasive treatment methods among patients are believed to contribute to this growth in the forecast period. Notable trends for the same period encompass advancements in long-acting vitamin B12 formulae, an upswing in the usage of home-based diagnostic kits, the adoption of Artificial Intelligence (AI) for anemia diagnosis, the surge in digital health monitoring tools, and improvement in diagnostic technology.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
What External And Internal Drivers Are Influencing The Pernicious Anemia Diagnosis And Treatment Market?
Growth in the pernicious anemia diagnosis and treatment market is likely to be spurred by the increasing occurrence of vitamin B12 deficiency. This deficiency arises when the body does not have sufficient vitamin B12 to facilitate the production of an adequate number of red blood cells, resulting in symptoms like fatigue, weakness, and neurological complications. The rise in vitamin B12 deficiency comes from the greater acceptance of plant-based diets that may lack ample natural B12 sources, subsequently leading to poor intake unless appropriate supplementation is administered. This deficiency plays a significant role in pernicious anemia diagnosis and treatment as limited B12 amounts impede the creation of red blood cells, directing physicians to provide B12 supplementation as a primary and successful treatment solution. For example, a study presented by the National Health Service (NHS), a UK-based government health entity, in February 2023 informed that both vitamin B12 and folate deficiencies are more widespread among the elderly, impacting nearly 1 in 10 individuals aged 75 or above and 1 in 20 aged between 65 and 74. Therefore, the increasing number of vitamin B12 deficiency cases is influencing growth in the pernicious anemia diagnosis and treatment market.
What Segmentation Insights Are Provided In The Pernicious Anemia Diagnosis And Treatment Market Research?
The pernicious anemia diagnosis and treatmentmarket covered in this report is segmented –
1) By Type: Complete Blood Count Test; Vitamin B12 Deficiency test; Intrinsic Factor Deficiency Test
2) By Treatment: Vitamin B12 Injections; Vitamin B12 Pills; Spray
3) By Route Of Administration: Injection; Oral; Intranasal
4) By End-User: Hospitals; Clinics; Diagnostic Centres; Other End-users
Subsegments:
1) By Complete Blood Count (CBC) Test: Red Blood Cell Count; Hemoglobin Concentration; Hematocrit Levels; Mean Corpuscular Volume (MCV); White Blood Cell Count; Platelet Count
2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test; Methylmalonic Acid (MMA) Test; Homocysteine Test; Holotranscobalamin (Active B12) Test
3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test; Parietal Cell Antibody Test; Schilling Test; Gastrin Level Test
Which Trends Are Likely To Redefine Growth Paths In The Pernicious Anemia Diagnosis And Treatment Market?
Key players in the market for the diagnosis and treatment of pernicious anemia are concentrating their efforts on the creation of novel solutions, such as vitamin B12 maintenance therapy solutions. These solutions aim to enhance patient adherence and the long-term handling of the disease. Vitamin B12 maintenance therapy solutions include a regular, continuous supplement regime via tablets, injections, or nasal sprays to maintain suitable B12 levels and avoid returning deficiency-related symptoms. As an example, Lupin Pharmaceuticals Inc., a pharmaceutical company based in India, introduced a cyanocobalamin nasal spray, 500 mcg/spray, in February 2024 as a non-invasive choice for vitamin B12 supplementation. This nasal spray provides a handy and efficient way for patients suffering from pernicious anemia who have difficulty with oral B12 forms. It aids in the improvement of B12 absorption and management of the B12 deficiency, thereby increasing patient compliance and improving treatment outcomes.
Who Are The Leading Companies Driving The Pernicious Anemia Diagnosis And Treatment Market?
Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, Amgen Inc., DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Daiichi Sankyo Co. Ltd., Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Pernicious Anemia Diagnosis And Treatment Market?
North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24360&type=smp
Browse Through More Reports Similar to the Global Pernicious Anemia Diagnosis And Treatment Market 2025, By The Business Research Company
Anemia And Other Blood Disorder Drugs Global Market Report 2025
Chemotherapy Induced Anemia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Hematology Drugs Global Market 2025
https://www.thebusinessresearchcompany.com/report/hematology-drugs-global-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
